Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Wang, Qiao; Peng, Hongling; Qi, Xiaorong; Wu, Min; Zhao, Xia

doi:10.1038/s41392-020-0199-6

Cited by 103 publications

(78 citation statements)

References 435 publications

(521 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, anti-angiogenic treatment can be used in combination with chemotherapy, which can induce, itself, renal toxicity. Bevacizumab, for example, has been approved in association with other chemotherapy drugs in non-small cell lung cancer (NSCLC), colorectal cancer, ovarian cancer, metastatic cervical cancer, and metastatic renal cell carcinoma (RCC) [ 35 , 112 , 159 , 162 , 163 , 164 ].…”

Section: Adverse Effects Of Anti-angiogenic Therapymentioning

confidence: 99%

Nephrotoxicity of Anti-Angiogenic Therapies

et al. 2021

View full text Add to dashboard Cite

The use of inhibitors of vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling for the treatment of cancer has increased over the last decade. This signaling pathway plays a fundamental role in angiogenesis and also in kidney physiology. The emergence of anti-angiogenic therapies has led to adverse nephrotoxic effects, despite improving the outcomes of patients. In this review, we will present the different anti-angiogenic therapies targeting the VEGFR pathway in association with the incidence of renal manifestations during their use. In addition, we will discuss, in detail, the pathophysiological mechanisms of frequent renal diseases such as hypertension, proteinuria, renal dysfunction, and electrolyte disorders. Finally, we will outline the cellular damage described following these therapies.

show abstract

Section: Adverse Effects Of Anti-angiogenic Therapymentioning

confidence: 99%

Nephrotoxicity of Anti-Angiogenic Therapies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This combination treatment nearly doubled the progression-free survival in HRD-positive tumors when compared to bevacizumab alone [ 62 ]. Finally, clinical trials examining the impact of multiple novel combinatorial strategies, including VEGF inhibitors (VEGFi) in combination with PARP inhibitors (PARPi) as well as anti-PD-1 inhibitors, alone or in combination with VEGFi and/or PARPi, are ongoing [ 63 ]. While significant advances in the molecular characterization of ovarian cancer have led to a better understanding of this disease, the prognosis has not significantly improved over the past several decades; poor prognosis is attributed to lack of early detection and resistance (inherent and acquired) to platinum-/taxane-based therapies [ 3 , 46 ].…”

Section: Clinical Characterization Of Breast and Ovarian Cancermentioning

confidence: 99%

“…As we have outlined above, patterns of genomic and proteomic alterations can define tissue- and histological-specific differences in underlying biology and can be used to define molecularly distinct subtypes of cancer, including breast and ovarian cancer [ 2 , 3 , 11 , 23 , 97 , 118 , 119 , 120 , 136 , 153 , 154 , 155 ]. These genomic and proteomic patterns can identify oncogenic mechanisms that contribute to disease development, progression and in some instance can serve as therapeutic targets or markers of therapeutic response [ 10 , 62 , 63 , 99 , 102 , 113 , 126 , 128 , 129 , 135 , 137 , 142 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 ]. However, single platform analyses can be limited in their ability to visualize altered signaling networks and oncogenic processes.…”

Section: Advances In Genomic Analyses Of Breast and Ovarian Cancermentioning

confidence: 99%

Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer

Khella

Mehta

et al. 2021

JPM

View full text Add to dashboard Cite

The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries.

show abstract

“…The advent of targeted therapies transformed the OC treatment landscape, both in the first line and in the recurrent clinical setting [ 2 , 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors

Nero

Ciccarone

Pietragalla

et al. 2021

Cancers

View full text Add to dashboard Cite

Ovarian cancer treatment strategy is mainly based on three pillars: cytoreductive surgery, platinum-based chemotherapy, and targeted therapies. The latter in the last decade has provided a remarkable improvement in progression free patients and, hopefully, in overall survival. In particular, poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors exploit BRCA 1/2 mutations and DNA damage response deficiencies, which are believed to concern up to 50% of high grade epithelial ovarian cancer cases. While these agents have an established role in ovarian cancer treatment strategy in BRCA mutated and homologous recombination deficient patients, an appropriate predictive molecular test to select patients is lacking in clinical practice. At the same time, the impressive results of immunotherapy in other malignancies, have opened the space for the introduction of immune-stimulatory drugs in ovarian cancer. Despite immune checkpoint inhibitors as a monotherapy bringing only modest efficacy when assessed in pretreated ovarian cancer patients, the combination with chemotherapy, anti-angiogenetics, PARP inhibitors, and radiotherapy is believed to warrant further investigation. We reviewed literature evidence on PARP inhibitors and immunotherapy in ovarian cancer treatment.

show abstract

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Cited by 103 publications

References 435 publications

Nephrotoxicity of Anti-Angiogenic Therapies

Nephrotoxicity of Anti-Angiogenic Therapies

Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors

Contact Info

Product

Resources

About